Analyzing immune markers in patients with osteoporosis
Immunological Markers for the Improvement of Diagnosis and Therapy of Osteoporosis
This study is testing if looking at immune markers in blood samples can help doctors diagnose osteoporosis earlier and improve treatment options for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Bonn Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Bonn, Northrhine Westfalia) |
| Trial ID | NCT05132348 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance the diagnosis of osteoporosis by investigating immunophenotyping in blood samples from patients diagnosed with the condition. It combines traditional diagnostic methods, such as medical history, clinical examination, and dual X-ray absorptiometry (DXA), with new approaches focusing on immune system markers. By identifying specific immunoregulatory markers associated with osteoporosis, the study seeks to improve early diagnosis and potentially inform future therapeutic strategies. The goal is to provide a non-invasive blood test that could lead to better management of osteoporosis.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients aged 18 and older who have been diagnosed with osteoporosis.
Not a fit: Patients who do not have a diagnosis of osteoporosis or those with secondary osteoporosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnosis of osteoporosis, improving patient outcomes.
How similar studies have performed: While the approach of using immunological markers in osteoporosis is promising, it is relatively novel and has not been extensively tested in previous studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (≥ 18 years) diagnosed with osteoporosis. * Written informed consent from the patient Exclusion Criteria: * Patients without diagnosed osteoporosis * Patients without written informed consent * Patients \< 18 years old * Patients with secondary osteoporosis
Where this trial is running
Bonn, Northrhine Westfalia
- University Hospital of Bonn — Bonn, Northrhine Westfalia, Germany (Recruiting)
Study contacts
- Principal investigator: Andreas Strauß, PD Dr. — physican
- Study coordinator: Andreas Strauß, PD Dr.
- Email: andreas.strauss@ukbonn.de
- Phone: 004922828714176
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.